experimentation to generate synthetic DNA elements that promote nuclear entry and transcriptional activity. These DNA cargos are built to work with existing lipid nanoparticle delivery systems, aiming to blend the durability of viral vectors with the safety and manufacturability of non-viral approaches. Gramics Bio’s lead therapeutic program targets cystic fibrosis with an intravenously delivered DNA therapeutic intended to treat lung cells across genotypes. Over time, the platform is intended to support additional applications in severe monogenic conditions affecting organs such as lung, kidney, and retina.